Bladder Capacity as an Objective Measure of Response to Intravesical Treatment of Newly Diagnosed Interstitial Cystitis: a Prospective Randomized Trial
Aim: The purpose of this study is to determine whether a change in the volume of water that a woman can hold in her bladder can be used to determine whether treatment for interstitial cystitis, dimethyl sulfoxide and triamcinolone or bupivicaine/ heparin/triamcinolone mixture, is working.
Principal Investigator: Peter K. Sand, MD
IRB Approval Number: EH11-081
Contact: call 224.251.3493 with questions regarding the study.

A Prospective, Non-Randomized, Parallel Cohort, Multi-center Study of Uphold LITE vs. Native Tissue for the Treatment of Women with Anterior/Apical Pelvic Organ Prolapse
Aim: The purpose of this research study is to compare two different standard of care treatments: a device (Uphold LITE) to a native tissue repair procedure for the treatment of symptoms for pelvic organ prolapse. Safety information and patient outcomes will be collected for three years and evaluated.
Principal Investigator: Peter K. Sand, MD
IRB Approval Number: EH13-301
Contact: call 224.251.3493 with questions regarding the study.

A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinence
Aim: The purpose of this study is to evaluate the safety and efficacy of a medical procedure in which your own muscle cells (AMDC-USR) are collected, processed, and then re-injected into the tissues of your urinary passage. This study will determine if the cells are safe and effective in treating stress urinary incontinence in females.
Principal Investigator: Peter K. Sand, MD
IRB Approval Number: EH13-455
Contact: call 224.251.3493 with questions regarding the study.

A Fidelity Measure for Pelvic Floor Physical Therapy in Female Pelvic Pain: A Validation Study
Aim: The purpose of this research study is to quantify the essential components of a pelvic floor physical therapy session and to determine the effect of adherence to a standard study protocol on patient reported outcomes of improvement.
Principal Investigator: Urogynecology f
IRB Approval Number: EH15-282
Contact: call 224.251.2374 with questions regarding the study.

The Risk of Cognitive Impairment in Patients Starting Anticholinergic Medication to Treat Overactive Bladder: A Prospective Trial
Aim: With this study, we plan to describe the risk of cognitive decline in patients starting treatment with anticholingeric medications for overactive bladder.
Principal Investigator: Roger Goldberg, MD
IRB Approval Number: EH16-059
Contact: call 224.251.2374 with questions regarding the study.